EUVIMEDEUVIMED entdecken
Kohortenstudie

Impact of Thrombophilia Testing on Clinical Management: A Retrospective Cohort Study

Hannah L McRae, Jens Müller, Heiko Rühl, Bernd Pötzsch

Hämostaseologie · 2026-10 · 46 (05) · 358-366

DOI: 10.1055/a-2447-5522 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Hämostaseologie, online erschienen am 10.12.2024. Verfasst von Hannah L McRae und 3 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Bonn, Institute for Experimental Hematology and Transfusion Medicine, Germany, Bonn. Hauptthemen laut MEDLINE: Thrombophilia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thrombophilia management is based on the personal and family history of thrombosis. Current guidelines recommend performing thrombophilia testing only when the results will change clinical management. To investigate to what extent treatment recommendations changed following thrombophilia testing, clinical and laboratory data of 255 patients with and without venous thromboembolism who underwent thrombophilia screening were assessed retrospectively. A local score based on clinical indicators for thrombophilia was used to assess the pretest probability of thrombophilia. A total of 144 patients (57.6%) were found to have a clear thrombophilic phenotype, of which 78 were predicted to have definite thrombophilia and considered for indefinite anticoagulation; 66 were likely to have thrombophilia and were considered for indefinite or prolonged anticoagulation. Eighty-three (32.5%) could not be clearly classified and 28 (11%) were asymptomatic. A thrombophilic risk factor was diagnosed in 98 (38.4%) patients; this included 64 of 144 (44.5%) patients with a clear thrombophilic phenotype and 26 of 83 (31.3%) patients who could not be easily classified. Treatment recommendations changed in 57 of 255 (22%) patients following thrombophilia testing. Eight patients were switched from direct oral anticoagulants to vitamin K antagonists due to confirmed triple-positive antiphospholipid syndrome. In 49 patients, the anticoagulant dose was either increased (n = 3) or treatment was prolonged (n = 46) following diagnosis of high-risk thrombophilia. Clinically, assessing thrombophilia probability score before thrombophilia testing improves thrombophilia management recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombophiliaHumansFemaleRetrospective StudiesMaleAnticoagulantsMiddle AgedAgedAdultRisk FactorsCohort Studies

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • University Hospital Bonn, Institute for Experimental Hematology and Transfusion Medicine, Germany, Bonn.

Zitieren

APA

McRae, H. L., Müller, J., Rühl, H., & Pötzsch, B. (2026). Impact of Thrombophilia Testing on Clinical Management: A Retrospective Cohort Study. Hämostaseologie, 46(05), 358-366. https://doi.org/10.1055/a-2447-5522

Vancouver

McRae HL, Müller J, Rühl H, Pötzsch B. Impact of Thrombophilia Testing on Clinical Management: A Retrospective Cohort Study. Hämostaseologie. 2026;46(05):358-366. doi:10.1055/a-2447-5522

BibTeX
@article{McRae2026,
  author = {McRae, Hannah L and Müller, Jens and Rühl, Heiko and Pötzsch, Bernd},
  title = {Impact of Thrombophilia Testing on Clinical Management: A Retrospective Cohort Study},
  journal = {Hämostaseologie},
  year = {2026},
  volume = {46},
  number = {05},
  pages = {358--366},
  doi = {10.1055/a-2447-5522}
}
Kostenlos starten →